EYPT Quote, Financials, Valuation and Earnings

Ocugen, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of -1144.46%. EyePoint Plc's return on equity of -83.61% beat Ocugen, Inc.'s return on equity of -848.82%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 183.46%. On the other hand Ocugen, Inc. has an analysts' consensus of $10.36 which suggests that it could grow by 317.88%. Given that Ocugen, Inc. has higher upside potential than EyePoint Plc, analysts believe Ocugen, Inc. is more attractive than EyePoint Plc.

EyePoint Plc has a beta of 1.725, which suggesting that the stock is 72.48% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 2.750, suggesting its more volatile than the S&P 500 by 175.048%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $620K, which are larger than Ocugen, Inc. quarterly revenues of -$193K. EyePoint Plc's net income of -$67.6M is lower than Ocugen, Inc.'s net income of -$17.7M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 30.81x versus 168.65x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of -487.96%. EyePoint Plc's return on equity of -83.61% beat Ocular Therapeutix, Inc.'s return on equity of -73.88%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 183.46%. On the other hand Ocular Therapeutix, Inc. has an analysts' consensus of $26.17 which suggests that it could grow by 198.71%. Given that Ocular Therapeutix, Inc. has higher upside potential than EyePoint Plc, analysts believe Ocular Therapeutix, Inc. is more attractive than EyePoint Plc.

EyePoint Plc has a beta of 1.725, which suggesting that the stock is 72.48% more volatile than S&P 500. In comparison Ocular Therapeutix, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.316%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Ocular Therapeutix, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $620K, which are smaller than Ocular Therapeutix, Inc. quarterly revenues of $13.3M. EyePoint Plc's net income of -$67.6M is lower than Ocular Therapeutix, Inc.'s net income of -$64.7M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Ocular Therapeutix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 30.81x versus 31.57x for Ocular Therapeutix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of 21.74%. EyePoint Plc's return on equity of -83.61% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 183.46%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $872.85 which suggests that it could grow by 17.04%. Given that EyePoint Plc has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Regeneron Pharmaceuticals, Inc..

EyePoint Plc has a beta of 1.725, which suggesting that the stock is 72.48% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.484%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.94 per share. EyePoint Plc pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

EyePoint Plc quarterly revenues are $620K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. EyePoint Plc's net income of -$67.6M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 30.81x versus 5.65x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -10904.68% compared to EyePoint Plc's net margin of --. EyePoint Plc's return on equity of -83.61% beat Viking Therapeutics, Inc.'s return on equity of -46.41%.

EyePoint Plc has a consensus price target of $37.42, signalling upside risk potential of 183.46%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $92.72 which suggests that it could grow by 160.24%. Given that EyePoint Plc has higher upside potential than Viking Therapeutics, Inc., analysts believe EyePoint Plc is more attractive than Viking Therapeutics, Inc..

EyePoint Plc has a beta of 1.725, which suggesting that the stock is 72.48% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.756, suggesting its less volatile than the S&P 500 by 24.38%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $620K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. EyePoint Plc's net income of -$67.6M is higher than Viking Therapeutics, Inc.'s net income of -$157.7M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 30.81x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.